Results 81 to 90 of about 21,301 (157)

Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell‐cycle, MAPK, and PI3K pathways

The Journal of Pathology, Volume 270, Issue 3, Page 380-395, November 2026.
Abstract Mucosal melanomas (MMs) are rare, aggressive cancers with poor outcomes and limited response to standard therapies. A significant knowledge gap exists regarding their genomic landscape and corresponding druggable targets. This study explores this issue through a multi‐omic analysis, including whole exome‐, RNA‐, and targeted sequencing, of ...
Matilde Monti, Martina Brigida Romanello, Luca Agnelli, Matteo Orlandi, Luca Bertoli, Sara Picinoli, Irene Pezzali, Giulio Eugenio Mandelli, Daniela Medicina, Giovanni Ribaudo, Adele Busico, Elena Conca, Vilma Pellegrini, Piera Balzarini, Daniele Gallucci, Anna Di Matteo, Davide Lombardi, Claudia Ghigna, Giancarlo Pruneri, Alessandra Gianoncelli, Marzia Rossato, William Vermi   +21 more
wiley   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp, Maikel Borg, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Katja Taxis, Frank G. A. Jansman   +5 more
wiley   +1 more source

Dabrafenib plus Trametinib: A breakthrough in pediatric low‐grade glioma therapy

Health Science Reports
Background and Aims Pediatric‐type low‐grade gliomas (pLGGs) are the most common solid tumors in children, with v‐raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development.
Marrium Sultan Dar, Nayab Shahid, Arisha Waqas, Yumna Arif Baig, Aimen Waqar Khan   +4 more
doaj   +1 more source

Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors

Journal of Cutaneous Pathology, Volume 53, Issue 11, Page 1042-1050, November 2026.
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He, Shaymaa Hegazy, Phyu P. Aung, Priyadharsini Nagarajan, Fiorinda Muhaj, Adrienne N. Choksi, Ana M. Ciurea, Kelly C. Nelson, Doina Ivan, Carlos A. Torres‐Cabala, Victor G. Prieto, Jonathan L. Curry   +11 more
wiley   +1 more source

Halofuginone induces ERK phosphorylation and synergizes with trametinib in gastric cancer cells

International Journal of Immunopathology and Pharmacology
Objective: The aim of this study was to investigate the effects of halofuginone (HF) on gastric cancer cells and whether the combination of HF and trametinib has synergistic effects.
Yuemin Sun, Peng Wang, Xiaofeng Bai, Liang Tian, Yuxin Zhong   +4 more
doaj   +1 more source

Trametinib as a targeted treatment in cardiac and lymphatic presentations of Noonan syndrome

Frontiers in Pediatrics
IntroductionRare pathogenic variants in the PTPN11, KRAS, SOS1 and RAF1 genes are the main molecular causes of Noonan syndrome (NS). Most are dominant gain-of-function variants that cause an overactivation of the RAS/MAPK signaling pathway leading to ...
Isabel De Brouchoven, Juan Lorand, Léon Bofferding, Arthur Sorlin, An Van Damme, Olivier Danhaive, Olivier Danhaive   +6 more
doaj   +1 more source

Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Scientific Reports
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are ...
Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Erkan Buket Ozmarasalı, Yasemin Sagdıc Karateke, Teoman Sakalar, Sendag Yaslikaya, Ilknur Deliktas Onur, Goncagul Akdag, Ali Ogul, Murad Guliyev, Elif Sahin, Ebru Engin Delipoyraz, Ali Alkan, Okan Aydın, Nurullah Ilhan, Ozkan Alan, Sinem Akbas, Yaprak Cağlar, Ali Kaan Guren, Nadiye Sever, Halil Ibrahim Ellez, Fatih Selcukbiricik, Mustafa Muhammed Atcı, Ahmet Bilici, Nebi Serkan Demirci, Tugba Basoglu, Cengiz Karacin, Ismail Oguz Kara, Bulent Yıldız, Turkkan Evrensel, Mustafa Karaca, Omer Dizdar, Elif Atag, Alpaslan Ozgun, Osman Kostek   +37 more
doaj   +1 more source

Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

IJU Case Reports
Introduction BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation A 60‐year‐old male was diagnosed with muscle‐invasive bladder cancer and underwent total cystectomy ...
Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya   +4 more
doaj   +1 more source

Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations

Heliyon
Background: Anaplastic thyroid cancer (ATC), a rare and aggressive malignancy with a poor prognosis, has shown promise with the approved dabrafenib/trametinib combination for BRAFV600E mutation.
Chiao-Ping Chen, Shu-Fu Lin, Chun-Nan Yeh, Wen-Kuan Huang, Yi-Ru Pan, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu   +7 more
doaj   +1 more source

RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor. [PDF]

Sci Adv
Chakraborty S, Jiang J, Camallonga JV, Gazgalis D, Gero TW, Tavares MT, Dittemore G, Tkacik E, Beyett TS, Jang DM, Ha BH, Gottlieb FH, Levitz T, Metivier RJ, Schmoker AM, Scott DA, Jeon H, Jänne PA, Eck MJ.   +18 more
europepmc   +1 more source